NovaBay® Pharmaceuticals (AMEX & TSX: NBY, www.novabaypharma), a clinical stage biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial, fungal, and viral infections, was featured on KGO-TV, the San Francisco Bay Area’s ABC affiliate. The segment, which aired on Monday, August 4, 2008, featured NovaBay’s key agent, NVC-422, as a new way of killing antibiotic resistant germs spreading through hospitals across the country.
Carolyn Johnson interviewed Dr. Ron Najafi, CEO of NovaBay® Pharmaceuticals, and discussed the composition of and opportunities for NVC-422. The compound is based upon small molecules that the white blood cells naturally produce to destroy microbes. NovaBay® has created and patented stable synthetic versions, known as the Aganocide® compounds, for topical uses; the goal is to take on all bacteria, including newer strains, which have grown resistant to antibiotics. The compound is being tested for the prevention of several hospital infections, including being developed as a nasal spray under the trademark, AgaNase™. If NVC-422 is successful, NovaBay® believes that it could help usher in a new era in medicines that combat antibiotic resistant bacteria and viruses. The segment can be viewed here
About NovaBay® Pharmaceuticals, Inc.
NovaBay® Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay® has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide® compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay® believes that Aganocide® compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including resistant bacteria such as MRSA. NovaBay® has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide® compounds in the eye, ear and sinus, and in contact lens solutions. The company also has a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay’s NeutroPhase product in wound care applications.
NovaBay™, Aganocide®, AgaNase™, and NeutroPhase™ are trademarks of NovaBay® Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projection, and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay® disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
The Investor Relations Group
Adam Holdsworth / Erica Ruderman / Brett Foley
Janet Vasquez / Laura Colontrelle